Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matisyahu Shulman

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Psychiatric Services (Washington, D.C.)|March 2, 2017
Home-Based Outpatient Telepsychiatry to Improve Adherence With Treatment Appointments: A Pilot StudyMatisyahu Shulman, Majnu John, John M Kane
American Journal of Therapeutics|February 16, 2022
Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of MedicinePeter Manu, Liliana M Rogozea, Matisyahu Shulman
CNS Drugs|May 8, 2019
Buprenorphine Treatment for Opioid Use Disorder: An OverviewMatisyahu Shulman, Jonathan M Wai, Edward V Nunes
Journal of Multidisciplinary Healthcare|November 11, 2014
Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachMatisyahu Shulman, Avraham Miller, Jason Misher, et al.
Journal of Addiction Medicine|February 15, 2022
Initiating Long-acting Injectable Naltrexone: Procedure for a Second Attempt After a First Attempt FailsMatisyahu Shulman, Mei Chen Hu, Edward V Nunes, et al.
AJR. American Journal of Roentgenology|May 22, 2009
Differences in aortic valve area measured with CT planimetry and echocardiography (continuity equation) are related to divergent estimates of left ventricular outflow tract areaEthan J Halpern, Raghuram Mallya, Matthew Sewell, et al.
Addiction Science & Clinical Practice|March 7, 2021
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"Matisyahu Shulman, Roger Weiss, John Rotrosen, et al.
Drug and Alcohol Dependence|February 1, 2025
Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trialMatisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, et al.
Addiction (Abingdon, England)|August 2, 2021
Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapseKara E Rudolph, Matisyahu Shulman, Marc Fishman, et al.
The American Journal on Addictions|August 10, 2018
Cognitive functioning and treatment outcomes in a randomized controlled trial of internet-delivered drug and alcohol treatmentMatisyahu Shulman, Aimee Campbell, Martina Pavlicova, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Psychiatric Services (Washington, D.C.)|March 2, 2017
Home-Based Outpatient Telepsychiatry to Improve Adherence With Treatment Appointments: A Pilot StudyMatisyahu Shulman, Majnu John, John M Kane
American Journal of Therapeutics|February 16, 2022
Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of MedicinePeter Manu, Liliana M Rogozea, Matisyahu Shulman
CNS Drugs|May 8, 2019
Buprenorphine Treatment for Opioid Use Disorder: An OverviewMatisyahu Shulman, Jonathan M Wai, Edward V Nunes
Journal of Multidisciplinary Healthcare|November 11, 2014
Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachMatisyahu Shulman, Avraham Miller, Jason Misher, et al.
Journal of Addiction Medicine|February 15, 2022
Initiating Long-acting Injectable Naltrexone: Procedure for a Second Attempt After a First Attempt FailsMatisyahu Shulman, Mei Chen Hu, Edward V Nunes, et al.
AJR. American Journal of Roentgenology|May 22, 2009
Differences in aortic valve area measured with CT planimetry and echocardiography (continuity equation) are related to divergent estimates of left ventricular outflow tract areaEthan J Halpern, Raghuram Mallya, Matthew Sewell, et al.
Addiction Science & Clinical Practice|March 7, 2021
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"Matisyahu Shulman, Roger Weiss, John Rotrosen, et al.
Drug and Alcohol Dependence|February 1, 2025
Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trialMatisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, et al.
Addiction (Abingdon, England)|August 2, 2021
Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapseKara E Rudolph, Matisyahu Shulman, Marc Fishman, et al.
The American Journal on Addictions|August 10, 2018
Cognitive functioning and treatment outcomes in a randomized controlled trial of internet-delivered drug and alcohol treatmentMatisyahu Shulman, Aimee Campbell, Martina Pavlicova, et al.
Pageof 4